- Home
- MDGL vs SF Comparison
MDGL vs SF Comparison
Compare MDGL & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDGL | SF |
|---|---|---|
| Founded | 2011 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 13.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MDGL | SF |
|---|---|---|
| Price | $482.19 | $128.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $597.54 | $133.75 |
| AVG Volume (30 Days) | 312.8K | ★ 672.0K |
| Earning Date | 02-25-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.43% |
| EPS Growth | N/A | ★ 2.14 |
| EPS | N/A | ★ 5.66 |
| Revenue | $740,640,000.00 | ★ $5,293,276,000.00 |
| Revenue This Year | $435.62 | $13.63 |
| Revenue Next Year | $52.67 | $12.05 |
| P/E Ratio | ★ N/A | $22.68 |
| Revenue Growth | ★ 864.21 | 11.76 |
| 52 Week Low | $265.00 | $73.27 |
| 52 Week High | $615.00 | $134.74 |
Technical Indicators
Market Signals| Indicator | MDGL | SF |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 49.51 |
| Support Level | $483.55 | $126.09 |
| Resistance Level | $511.94 | $132.04 |
| Average True Range (ATR) | 23.79 | 3.41 |
| MACD | -6.68 | -0.42 |
| Stochastic Oscillator | 12.67 | 31.56 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.0 billion in revenue in 2024, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.